StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Alaunos Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Alaunos Therapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0. The highest annual figure on record is $24.12M in fiscal 2021.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$16.77M-30.5%
FY2021Dec 31, 2021$24.12M–
FY2020Dec 31, 2020$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0–
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$10.99M-54.8%
Q4 FY2022Dec 31, 2022$16.77M-30.5%
Q3 FY2022Sep 30, 2022$22.67M-6.4%
Q2 FY2022Jun 30, 2022$24.52M–
Q1 FY2022Mar 31, 2022$24.32M–
Q4 FY2021Dec 31, 2021$24.12M–
Q3 FY2021Sep 30, 2021$24.21M–
Q4 FY2020Dec 31, 2020$0–

More Alaunos Therapeutics figures

See a number that looks wrong?